Monoacylglycerol lipase inhibitor - Janssen Pharmaceutica
Alternative Names: Small molecule MGLLiLatest Information Update: 28 Aug 2025
At a glance
- Originator Janssen Pharmaceutica
- Class Azabicyclo compounds; Behavioural disorder therapies; Small molecules
- Mechanism of Action Monoacylglycerol lipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Psychiatric disorders
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in Psychiatric-disorders in Belgium
- 08 Aug 2022 Monoacylglycerol lipase inhibitor - Janssen Pharmaceutica is available for licensing as of 25 Jul 2022. https://www.janssen.com/belgium/collaboration
- 25 Jul 2022 Phase-I clinical trials in Psychiatric disorders in Belgium (unspecified route) before July 2022 (Johnson and Johnson pipeline, July 2022)